17-beta-hydroxysteroid dehydrogenase deficiency laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(2 intermediate revisions by 2 users not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{Abdulkerim}}
{{CMG}}; {{AE}} {{Abdulkerim}}
==Overview==
==Overview==
*Increased serum androstenedione and decreased serum [[testosterone]]/[[androstenedione]] ratios after [[hCG]] [[stimulation]]. The definitive diagnosis can be made from [[Genetic testing]].
Increased serum androstenedione and decreased serum [[testosterone]]/[[androstenedione]] ratios after [[hCG]] [[stimulation]]. The definitive diagnosis can be made from [[Genetic testing]].


==Laboratory findings==
==Laboratory findings==
*Increased serum androstenedione and decreased serum [[testosterone]]/[[androstenedione]] ratios after [[hCG]] [[stimulation]].  
*Increased serum [[androstenedione]] and decreased serum [[testosterone]]/[[androstenedione]] ratios after [[hCG]] [[stimulation]]. However, low T/A ratios are not specific for 17βHSD3 deficiency, but are sometimes also found in patients with other defects in [[testosterone]] [[synthesis]] or [[Leydig cell]] [[hypoplasia]]. Therefore, T/A ratios should only be used when a hCG-stimulated response of serum testosterone or/and serum androstenedione is observed.
*The definitive diagnosis can be made from [[Genetic testing]].<ref name="pmid10599740">{{cite journal| author=Boehmer AL, Brinkmann AO, Sandkuijl LA, Halley DJ, Niermeijer MF, Andersson S | display-authors=etal| title=17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. | journal=J Clin Endocrinol Metab | year= 1999 | volume= 84 | issue= 12 | pages= 4713-21 | pmid=10599740 | doi=10.1210/jcem.84.12.6174 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10599740  }} </ref>
*The definitive diagnosis can be made from [[Genetic testing]].<ref name="pmid10599740">{{cite journal| author=Boehmer AL, Brinkmann AO, Sandkuijl LA, Halley DJ, Niermeijer MF, Andersson S | display-authors=etal| title=17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. | journal=J Clin Endocrinol Metab | year= 1999 | volume= 84 | issue= 12 | pages= 4713-21 | pmid=10599740 | doi=10.1210/jcem.84.12.6174 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10599740  }} </ref>
==References==
==References==
Line 16: Line 16:
[[Category:Endocrinology]]
[[Category:Endocrinology]]
[[Category:Genetic disorders]]
[[Category:Genetic disorders]]
[[Category:needs english review]]

Latest revision as of 07:49, 20 October 2022

17-beta-hydroxysteroid dehydrogenase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Molecular Genetic Studies

Genotyping

X Ray

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

17-beta-hydroxysteroid dehydrogenase deficiency laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 17-beta-hydroxysteroid dehydrogenase deficiency laboratory findings

CDC on 17-beta-hydroxysteroid dehydrogenase deficiency laboratory findings

17-beta-hydroxysteroid dehydrogenase deficiency laboratory findings in the news

Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency laboratory findings

Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency

Risk calculators and risk factors for 17-beta-hydroxysteroid dehydrogenase deficiency laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]

Overview

Increased serum androstenedione and decreased serum testosterone/androstenedione ratios after hCG stimulation. The definitive diagnosis can be made from Genetic testing.

Laboratory findings

References

  1. Boehmer AL, Brinkmann AO, Sandkuijl LA, Halley DJ, Niermeijer MF, Andersson S; et al. (1999). "17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations". J Clin Endocrinol Metab. 84 (12): 4713–21. doi:10.1210/jcem.84.12.6174. PMID 10599740.

Template:WH Template:WS